A reappraisal of the association between Dysbindin (DTNBP1) and schizophrenia in a large combined case–control and family-based sample of German ancestry
Received 19 August 2009; received in revised form 8 December 2009; accepted 20 December 2009. published online 18 January 2010.
Abstract
Background
Dysbindin (DTNBP1) is a widely studied candidate gene for schizophrenia (SCZ); however, inconsistent results across studies triggered skepticism towards the validity of the findings. In this HapMap-based study, we reappraised the association between Dysbindin and SCZ in a large sample of German ethnicity.
Method
Six hundred thirty-four cases with DSM-IV SCZ, 776 controls, and 180 parent–offspring trios were genotyped for 38 Dysbindin SNPs. We also studied two phenotypically-defined subsamples: 147 patients with a positive family history of SCZ (FH-SCZ+) and SCZ patients characterized for cognitive performance with Trail-Making Tests A and B (TMT-A: n=219; TMT-B: n=247). Given previous evidence of gene–gene interactions in SCZ involving the COMT gene, we also assessed epistatic interactions between Dysbindin markers and 14 SNPs in COMT.
Results
No association was detected between Dysbindin markers and SCZ, or in the FH-SCZ+ subgroup. Only one marker (rs1047631, previously reported to be part of a risk haplotype), showed a nominally significant association with performance on TMT-A and TMT-B; these findings did not remain significant after correction for multiple comparisons. Similarly, no pair-wise epistatic interactions between Dysbindin and COMT markers remained significant after correction for 504 pair-wise comparisons.
Conclusions
Our results, based on one of the largest samples of European Caucasians and using narrowly-defined criteria for SCZ, do not support the etiological involvement of Dysbindin markers in SCZ. Larger samples may be needed in order to unravel Dysbindin's possible role in the genetic basis of proposed intermediate phenotypes of SCZ or to detect epistatic interactions.
aDivision of Genetic Epidemiology, Central Institute of Mental Health, Mannheim, Germany
bUnit on the Genetic Basis of Mood and Anxiety Disorders, NIMH, NIH, Bethesda, USA
cDepartment of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany
dInstitute of Human Genetics, University of Bonn, Bonn, Germany
eDepartment of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany
Corresponding author. Unit on the Genetic Basis of Mood and Anxiety Disorders, National Institute of Mental Health (NIMH), National Institutes of Health (NIH), 35 Convent Drive, Bldg. 35, Rm 1A205, MSC 3719, Bethesda, MD 20892-3719, USA. Tel.: +1 301 451 7213; fax: +1 301 402 9081.
ABSTRACT